Moayyedi P, Feltbower R, Crocombe W, Mason S, Atha P, Brown J, Dowell A C, Richards I D, Axon A T
Centre for Digestive Diseases, The General Infirmary at Leeds, Leeds, UK.
Aliment Pharmacol Ther. 2000 Jun;14(6):719-28. doi: 10.1046/j.1365-2036.2000.00767.x.
Helicobacter pylori screening and treatment has been proposed as a cost-effective method of preventing gastric cancer.
To assess, in a randomized controlled trial, the efficacy of therapy in eradicating H. pylori as part of a screening programme, and to report the adverse events associated with this strategy.
Subjects between the ages of 40-49 years were randomly selected from the lists of 36 primary care centres. Participants attended their local practice and H. pylori status was determined by 13C-urea breath test. Infected subjects were randomized to receive omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. for 7 days (OCT) or identical placebos. Eradication was determined by a 13C-urea breath test 6 months and 2 years after the first visit. Successful eradication was defined as two negative 13C-urea breath tests or one negative and one missing test. Adverse events and compliance were assessed at the 6-month visit.
A total of 32 929 subjects were invited to attend, 8407 were evaluable, and 2329 (28%) of these were H. pylori-positive. A total of 1161 subjects were randomized to OCT and 1163 to placebo; over 80% returned for a repeat 13C-urea breath test on at least one occasion. The eradication rates in those allocated to OCT were as follows: intention-to-treat, 710 out of 1161 (61%; 95% confidence interval: 58-64%); evaluable 710 out of 967 (73%; 95% CI: 71-76%); took all medication 645 out of 769 (84%; 95% CI: 81-87%). Adverse events occurred in 45% of the treatment group and in 18% of the placebo group (relative risk 2.5; 95% CI: 2.1-2.9). Compliance, male gender, no antibiotic prescription in the subsequent 2 years and experiencing a bitter taste with the medication were independently associated with treatment success.
The OCT regimen has an eradication rate of 61% in intention-to-treat analysis and is therefore less successful in treating H. pylori as part of a screening programme compared with hospital studies in dyspeptic patients.
幽门螺杆菌筛查与治疗已被提议作为预防胃癌的一种具有成本效益的方法。
在一项随机对照试验中,评估作为筛查计划一部分的治疗方案根除幽门螺杆菌的疗效,并报告与该策略相关的不良事件。
从36个基层医疗中心的名单中随机选取40至49岁的受试者。参与者前往当地医疗机构,通过13C尿素呼气试验确定幽门螺杆菌感染状况。感染的受试者被随机分为两组,一组接受奥美拉唑20毫克每日两次、克拉霉素250毫克每日两次和替硝唑500毫克每日两次,疗程7天(OCT组),另一组接受相同的安慰剂。在首次就诊后6个月和2年时,通过13C尿素呼气试验确定根除情况。成功根除定义为两次13C尿素呼气试验结果均为阴性,或一次阴性且一次检测缺失。在6个月的随访中评估不良事件和依从性。
共邀请了32929名受试者就诊,8407名可评估,其中2329名(28%)幽门螺杆菌呈阳性。共有1161名受试者被随机分配至OCT组,1163名被分配至安慰剂组;超过80%的受试者至少有一次返回进行重复13C尿素呼气试验。分配至OCT组的受试者的根除率如下:意向性分析中,1161名中有710名(61%;95%置信区间:58 - 64%);可评估人群中,967名中有710名(73%;95%置信区间:71 - 76%);服用全部药物的人群中,769名中有645名(84%;95%置信区间:81 - 87%)。治疗组45%的受试者出现不良事件,安慰剂组为18%(相对风险2.5;95%置信区间:2.1 - 2.9)。依从性、男性、在随后2年未开具抗生素处方以及服药时出现口苦与治疗成功独立相关。
在意向性分析中,OCT方案的根除率为61%,因此与针对消化不良患者的医院研究相比,作为筛查计划的一部分治疗幽门螺杆菌的成功率较低。